Curated News
By: NewsRamp Editorial Staff
August 19, 2026
SS Innovations Reports Record Q2 Revenue, Up 39.4%
TLDR
- SS Innovations' Q2 revenue surged 39.4% to $13.9M, outpacing prior year, signaling strong market traction for SSi Mantra.
- SS Innovations' Q2 revenue growth to $13.9M was driven by a 30.4% increase in SSi Mantra installations, with 224 systems now deployed.
- SS Innovations' expanding SSi Mantra installations enable more patients worldwide to access advanced robotic surgery, improving healthcare outcomes.
- SS Innovations' SSi Mantra has achieved 12,272 cumulative surgeries across 12 countries, with telesurgery expanding its reach.
Impact - Why it Matters
The continued growth of SS Innovations and its SSi Mantra system signals a transformative shift in surgical robotics, making advanced minimally invasive surgery more accessible globally. As the company expands its installed base and works toward regulatory approvals in the U.S. and Europe, patients may benefit from improved outcomes and shorter recovery times. Investors should note the company's strong financial performance and potential catalysts ahead.
Summary
SS Innovations International (NASDAQ: SSII), a leader in surgical robotic technology, has announced record-breaking second-quarter 2026 revenue of $13.9 million, marking a 39.4% increase year-over-year. The company's first-half revenue reached $25.0 million, a substantial 65.6% jump from the same period in 2025. This growth is driven by the rising demand for its SSi Mantra surgical robotic system, with 30 new installations in Q2, bringing the total installed base to 224 systems across 12 countries. The company has also achieved a milestone of 12,272 cumulative surgeries performed using the SSi Mantra system.
Gross profit for the quarter increased 20.0% to $7.1 million, although gross margin dipped to 50.9% from 59.1% in the prior year. For the first half, gross profit rose 77.5% to $12.4 million, with improved margins. These financial results underscore the company's rapid expansion in the surgical robotics market.
Looking ahead, SS Innovations is targeting FDA clearance for SSi Mantra by the first quarter of 2027 and CE marking in Europe by the end of 2026, which could serve as significant catalysts. The company's telesurgery capabilities are also enhancing the clinical profile of the system. As installations remain the primary growth driver, the company's momentum is expected to continue. For more details, read the full press release on NEWMEDIAWIRE and explore additional information on SS Innovations International (NASDAQ: SSII).
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, SS Innovations Reports Record Q2 Revenue, Up 39.4%
